Navigation Links
338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
Date:9/4/2008

e subsequent commercial introduction of Polidocanol."

"For years, Polidocanol has been the worldwide standard for sclerotherapy of spider veins outside of the United States, and I am very excited about the prospect of being able to offer this treatment option to my patients in the future," said Robert Weiss, MD, President-Elect of the American Society for Dermatologic Surgery (ASDS) and Associate Professor, Dermatology at Johns Hopkins University School of Medicine, Baltimore, Maryland. "If Polidocanol becomes available in the United States, the physician community will have an important additional tool in their aesthetic treatment portfolio."

Kreussler, the company that developed Polidocanol as a sclerotherapy agent and has commercialized this product throughout the world over the past 40 years, conducted the pivotal clinical study pursuant to a special protocol assessment agreed to with FDA in 2006. The EASI study was specifically designed to provide the pivotal clinical data for the FDA related to the open New Drug Application (NDA) for Polidocanol. The final clinical study report on the EASI study has been submitted to FDA as an amendment to the existing NDA. In addition to this clinical report, Kreussler is completing manufacturing documentation for a newly expanded manufacturing facility. Consistent with the previously reported expected timeline for completion of the NDA submission, the manufacturing documentation is expected to be completed and submitted to FDA before the end of calendar year 2008.

BioForm Medical and Kreussler entered into an agreement in 2007 wherein BioForm will have exclusive U.S. rights to sell Polidocanol supplied by Kreussler upon FDA approval, and BioForm will pay Kreussler a royalty and transfer price for the supplied material, and development and commercialization milestone payments.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, Calif
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Agendia Launches TargetPrint(R) for Breast Cancer Patients
4. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
5. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
6. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
7. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
9. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
10. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
11. Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...NE RESULTS OF FIRST PHASE III TRIAL SHOW SIGNIFICA...EMENT IN DAILY FUNCTION, IN, ...if., and BRUSSELS, Belgium, Nov. 20 /PRNewswire-Fi... JAZZ ) and UCB (Euronext Brussels: UCB),announce... the first of two,Phase III pivotal clinical tria...
(Date:11/20/2008)... 20 Duska Therapeutics,... that it has submitted its,pivotal Phase 3 ATPace...l,Protocol Assessment (SPA) procedure with the U....ubject to securing an agreement with the FDA, Dusk...le-blind, placebo-controlled and randomized Phase ...
(Date:11/20/2008)...vember 20 The Scandinavian-based d...nced results of studies on its,lead antimicrobial...on, DC,the studies showed that the novel lytic p...fect, significantly better towards killing Staphyl...rketed gold standard drugs. In,addition to this i...
(Date:11/19/2008)...port basic findings on critical enzyme,s regulatio...t an array of disorders , , MEMPHIS, Tenn.,... St. Jude Children,s Research Hospital have gained... enzyme workhorses called calpains. , , As...tion in many cellular processes, including the mov...
Breaking Medicine Technology:Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3National Federation of the Blind to Award 24100 000 7690 1National Federation of the Blind to Award 24100 000 7690 2Inspirational Medical Teachers Honored with Mentor Awards from the American Society of Hematology 7685 1Inspirational Medical Teachers Honored with Mentor Awards from the American Society of Hematology 7685 2ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2082 1ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2082 2New choices for patients 3A Transfusion free medicine for Jehovahs Witnesses and transfusion wary 7681 1New choices for patients 3A Transfusion free medicine for Jehovahs Witnesses and transfusion wary 7681 2
...IRE)--Mar 27, 2007 - Interleukin,Genetics, Inc. (A...lifornia San Diego today reported at the American ...ions between coronary artery,disease (CAD) and bot...ppear to be dependent on pro-inflammatory variants...tion titled "The Influence of Oxidized,Phospholipi...
...l for Vaccine Delivery System, NYON, Switzerland, ...Corporation announced today that the Company,s HIV...human primate model.,Mucosal IgA antibodies are co...infection by HIV. The data were presented by,Sylva...er in an,oral presentation, "Without Mucosal Adjuv...
Other Medicine Technology:ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 2ACC Presentation Indicates Interleukin-1 Gene Variants Determine,Increased Risk for Coronary Artery Disease from Oxidized,Phospholipids 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 2Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 3Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting,Protective Antibody Response in Mucosal Tissues of Non-Human,Primate Model 4
(Date:11/21/2008)... preterm labor , , FRIDAY, Nov. 21 (Heal...witch that activates the uterine muscles for contr...to therapies for preterm labor. , The molecule... surface of these uterine muscle cells, keeping th... researchers from Dartmouth Medical School in New ...
(Date:11/21/2008)...ate University College of Medicine research team l...w layer of regulation in the cell division cycle, ... way cancer begins. , Wang, an assistant profess...ne, said the findings will lead to an improved abi...gn of new drugs that kill cancer cells by inhibiti...
(Date:11/21/2008)...FirstCall/ -- Heska Corporation,(Nasdaq: HSKA )...ociety of,Security Analysts, 12th Annual Biotech ...08 at 1177 Avenue of the Americas, 2nd Floor in Ne...n at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain T...r two weeks,following the presentation through a ...
(Date:11/21/2008)... future antibiotic resistance from widespread use ...- People with moderate to severe chronic obstructi...the frequency of exacerbations through a regular, .... , The study, published in the first issue fo... and Critical Care Medicine , found that twice-dai...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2
...aimed to prevent more sudden deaths than defibrill... defibrillators according to US scientists.// Rese...mpared such preventive strategies by food suppleme... computer-simulated community of 100,000 people th...
...and why some people are hairier than others may ha...s.// The molecular mechanisms that determine whic...es, deciding the body's hair pattern has been disc...niversity of Manchester. This study on mice will ...
...wo-thirds of the people in the US do not wash thei...t had been newly formed had conducted the survey o... that the participants had been chosen from around..., United Arab Emirates, India, Malaysia, and South...
...n commissioned by the Australian government states... might be an cost effective option to control// th...rt also stated that to have found the various prog...ive, but raised questions about the effectiveness ...
Other Medicine News:Health News:Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers 2
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL.
...pendorf Reference Series 2000 Pipette is a synonym...t and robust design, and superior operating comfor...perate the measuring stroke and blow-out as well a...pette/tip" system ensures utmost accuracy and prec...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M
Since 1991 Intersurgical Incorporated manufactures high efficiency breathing filters, heat and moisture exchangers, ventilator circuits, oxygen therapy products, hand-held nebulizers and an extensive
Medicine Products: